Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,509.01 +33.92 (+0.62%) Dow
39,331.85 +162.33 (+0.41%) Nasdaq
18,028.76 +149.46 (+0.84%) Bitcoin USD
60,515.98 -2,046.60 (-3.27%) CMC Crypto 200
1,305.00 -29.92 (-2.24%)
CHRS Nov 2024 1.000 call
| Previous close | 0.9000 |
| Open | 0.6100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.6000 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireCoherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology –REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to commercialize
GlobeNewswireCoherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise Rita Karachun Rita Karachun - Coherus Director REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Kar
- GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
